Newswise — April 12, 2016, NEW YORK, NY – Ludwig Cancer Research released today the full scope of advances presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in New Orleans, La., April 16–20. Research conducted by more than 70 Ludwig scientists will be presented in symposiums, plenaries and poster sessions, and Ludwig researchers will participate in several workshops and meet-the-expert sessions over the course of the Meeting.

“The AACR Annual Meeting is a principle forum for Ludwig researchers to forge collaborations and discuss long-term strategies for applying our discoveries to develop new interventions for the prevention, diagnosis and treatment of cancer,” said David Lane, PhD, Scientific Director, Ludwig Institute for Cancer Research.

Ludwig scientists will share insights and new data at the Meeting on discoveries stemming from both basic and translational research. Presentations on basic research will cover areas such as cancer genomics, tumor cell diversity, intracellular signaling, the development of “liquid biopsies” and a variety of studies on tumor immunology.

Ludwig presentations on translational and clinical research will cover—among many other things—immunotherapeutic strategies for a variety of cancers, the long-term survival of melanoma patients who received anti-PD-1 therapy, the design and initial clinical evaluation of an adoptive T cell therapy against a common cancer antigen and the relationship between inflammation, obesity and tumor progression in pancreatic cancer.

Click here for a comprehensive list of Ludwig scientists’ activities at the Meeting.

# # #

About Ludwig Cancer ResearchLudwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested nearly $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit http://www.ludwigcancerresearch.org.

For further information please contact Rachel Steinhardt, [email protected] or +1-212-450-1582.